WEST FARGO, N.D., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, announced today it will release financial results for the second quarter July 31, 2025, on Thursday, August 28, 2025, followed by an investor conference call at 7:30 a.m. Central time (8:30 a.m. Eastern time). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. International callers can dial (201) 3 ...

Core Insights - Descartes Systems Group has been recognized as the leading provider of software as a service (SaaS) and cloud-based hosting services for transportation management systems (TMS) according to ARC Advisory Group's report for 2024-2029 [1][2] - The company is also noted as a top provider in fleet management applications and planning and execution segments of the TMS market [1][2] - The report highlights a growing demand for real-time visibility solutions, with SaaS providers like Descartes experiencing faster growth compared to those using legacy models [2] Company Overview - Descartes focuses on improving productivity, security, and sustainability for logistics-intensive businesses through its modular SaaS solutions [5] - The company has made strategic investments in SaaS-based solutions, including the acquisition of 3GTMS and MyCarrierPortal to enhance its service offerings and combat cargo fraud [2][5] Industry Context - The ARC report provides a comprehensive five-year global market forecast and analysis of leading TMS providers, emphasizing the importance of real-time visibility in logistics [2] - Descartes serves a diverse range of industries, including carriers, food and beverage manufacturers, retailers, and logistics brokers, indicating its broad market reach [2][6]

Please find enclosed Eika Boligkreditt AS' interim report for the second quarter and first half of 2025. The report is also available on http://eikbol.no/ Attachment Eika Boligkreditt AS - Report 2Q 2025 ...

Castellum, Inc. Announces Aggregate Warrant Exercises Raising Additional Proceeds of Approximately $4.5 Million - Castellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”) announces investors have exercised stock warrants, an aggregate of 3,673,666 warrants, for total gross proceeds of $4,481,873 - www.castellumus.com VIENNA, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”), a cybersecurity, electronic warfare, and software engineering services company ...

Operational Discipline, Focus on Core Offerings, and AI-Enabled GCC Delivery Help to Drive Sustainable, Profitable GrowthNEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (“Aeries” or “the Company”) (Nasdaq: AERT), a global leader in AI-powered business transformation and Global Capability Center (GCC) services, today announced financial results for the first quarter ended June 30, 2025 — the strongest first quarter in Company history, delivering positive operating cash flow and a $17.0 mi ...

Anchorage Alaska, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3) ) is pleased to provide an update where both Alaska State government officials and the Australian Consular-General have shown strong support for the Estelle Gold and Critical Minerals Project in recent meetings with Nova. Highlights Alaska State Governor, Mike Dunleavy (Figure 1) continues to show strong support for the Estelle Project in a meeting with Nova CEO Christopher ...

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and com ...

Core Insights - The company is experiencing significant growth in real estate development across its key markets, with a notable increase in revenue and profitability in the first half of 2025 compared to the same period in 2024 [14][21][24]. Real Estate Development - In Tallinn, the Kalaranna development is nearing completion, with 76 sold apartments handed over and an overall sales rate of 60.7% as of Q2 2025 [1]. - The Kristiine City area is seeing continued development, with four projects adding approximately 35,000 sqm of gross building area and around 350 residential units [2]. - The White Building project in Kristiine City has achieved a sellout rate of 62.4%, with completion expected by November-December 2025 [3]. - A new 7-story residential building with 90 units is under construction, with a current sellout rate of 12.2% and expected completion in October-November 2026 [4]. - In Riga, the Blue Marine project is in preparation, with 96 residential units planned following the successful sales of River Breeze Residence [5][6]. - In Vilnius, the Šaltinių Namai Attico project is progressing with a sellout rate of nearly 40% for villas and over 10% for the commercial building, with substantial completion expected by the end of 2025 [7]. Financial Performance - Total revenue for the first half of 2025 was €28.5 million, a significant increase from €6.9 million in the same period of 2024, with Q2 revenue reaching €16.1 million compared to €3.9 million in 2024 [14][21]. - Gross profit for the first six months of 2025 increased to €10.2 million from €2.4 million in 2024, with a gross profit margin of 36% [17][21]. - The operating result improved to a profit of €7.5 million in the first half of 2025, compared to a loss of €0.9 million in the same period in 2024 [18][21]. - The net result for the first half of 2025 was a profit of €6.2 million, compared to a loss of €3.0 million in 2024 [19][21]. - Cash generated from operating activities was €8.5 million in the first half of 2025, compared to a cash outflow of €4.5 million in the same period of 2024 [20][21]. Market Outlook - The company is well-positioned to capitalize on improving macroeconomic conditions and is focused on disciplined execution and strategic development [13][14]. - The real estate market is expected to normalize by the end of 2025, despite previous slowdowns due to rising interest rates [12].

Core Insights - Battalion Oil Corporation reported its financial and operational results for Q2 2025, highlighting a net loss of $3.5 million and an adjusted diluted net loss of $10.6 million [6][9][12]. Operational Highlights - The company completed its 2025 six-well drilling plan ahead of schedule and under budget, with initial production rates from the new wells outperforming legacy wells [2][4]. - The acid gas injection facility treated approximately 2.2 Bcf of gas, but ceased operations on August 11, 2025, leading to a temporary shutdown of part of the Monument Draw field [3][8]. Financial Performance - Average daily net production was 12,989 Boe/d (49% oil), with total operating revenue of $42.8 million, a decrease from $49.1 million in Q2 2024 [4][6]. - The decline in revenue was primarily due to a $5.93 decrease per Boe in average realized prices, partially offset by a 132 Boe/d increase in production [4][6]. - Lease operating and workover expenses increased to $10.98 per Boe, while general and administrative expenses decreased to $2.17 per Boe [5][6]. Liquidity and Balance Sheet - As of June 30, 2025, the company had $219.4 million in term loan indebtedness and total liquidity of $44.6 million [9][15]. - Current assets increased to $83.5 million, with cash and cash equivalents at $44.6 million, up from $19.7 million a year earlier [15][9]. Production and Pricing Data - Crude oil production for Q2 2025 was 584 MBbls, with an average price of $62.14 per Bbl, down from $79.20 in Q2 2024 [20][21]. - Total production volumes for the quarter were 1,182 MBoe, with an average daily production of 12,989 Boe/d [20][21].

Core Insights - Fennec Pharmaceuticals reported total net revenues of $9.7 million for Q2 2025, reflecting a 33% increase compared to the same quarter in 2024, driven by growth in large community practices and academic centers [1][3][9] - The company has seen a successful uptake of its product PEDMARQSI in the UK and Germany, with plans for additional EU launches [1][3] - The management anticipates results from a clinical trial in Japan (STS-J01) in the second half of 2025, which may lead to registration and potential licensing opportunities [1][3] Financial Performance - Net product sales for Q2 2025 were approximately $9.7 million, up from $7.3 million in Q2 2024, attributed to growth in the adolescent and young adult (AYA) population [9][11] - Selling and marketing expenses decreased to $4.4 million in Q2 2025 from $4.6 million in Q2 2024, while general and administrative expenses increased slightly to $7.0 million from $6.9 million [9][11] - The company reported a net loss of $3.2 million for Q2 2025, compared to a net loss of $5.6 million in Q2 2024 [11] Business Highlights - Fennec's segmentation model and data-driven targeting have led to significant growth in both new and repeat customers, particularly in large community and academic practices [6] - A large national oncology group has added PEDMARK to its formulary for patients under 40, indicating growing recognition of the need to protect younger patients from cisplatin-induced hearing loss [6] - The NCODA PQI issued for PEDMARK aims to provide clinical data and guidance for healthcare professionals managing patients on cancer therapies [6] Upcoming Events - Fennec will ring the NASDAQ closing bell on September 5, 2025, alongside PEDMARK patients and their families [10] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [10] Product Information - PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients [15][19] - The product has received Orphan Drug Exclusivity in the U.S. and is commercially available in the U.K. and Germany under the brand name PEDMARQSI [28][30]